logo BDSP

Base documentaire


  1. Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients.

    Article - En anglais

    Background Ticlopidine, an antiplatelet agent, when compared with aspirin has been found to reduce the risk of stroke in high-risk patients, ie, those with recent transient ischemic attack, reversible ischemic neurological deficit, amaurosis fugax, or minor stroke.

    Its cost-effectiveness in such use, however, is unknown.

    Methods We developed a model of primary stroke prevention in which a hypothetical cohort of 100 high-risk men and women 65 years of age was assumed to receive either ticlopidine (500 mg daily) or aspirin (1300 mg daily).

    Using published data, we estimated lifetime incidence of stroke, life expectancy (unadjusted and adjusted for changes in quality of life), and lifetime medical care costs associated with each therapy.

    Mots-clés Pascal : Accident cérébrovasculaire, Homme, Traitement, Chimiothérapie, Prévention, Ticlopidine, Inhibiteur thromboagrégation, Coût, Economie santé, Analyse coût efficacité, Système nerveux pathologie, Système nerveux central pathologie, Encéphale pathologie, Cérébrovasculaire pathologie, Appareil circulatoire pathologie, Vaisseau sanguin pathologie

    Mots-clés Pascal anglais : Stroke, Human, Treatment, Chemotherapy, Prevention, Antiplatelet agent, Costs, Health economy, Cost efficiency analysis, Nervous system diseases, Central nervous system disease, Cerebral disorder, Cerebrovascular disease, Cardiovascular disease, Vascular disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 94-0474057

    Code Inist : 002B02F04. Création : 199501.